ストックスクリーナーアプリを入手
5.77
5.68%
0.31
前日終値:
$5.46
開ける：
$5.46
24時間の取引高:
1.17M
Relative Volume:
0.63
時価総額：
$418.29M
収益：
$11.40B
当期純損益:
$-95.73M
株価収益率:
-2.3551
EPS:
-2.45
ネットキャッシュフロー:
$-64.37M
1週間 パフォーマンス:
+12.26%
1か月 パフォーマンス:
-10.82%
6か月 パフォーマンス:
-10.12%
1年 パフォーマンス:
-39.45%
1日の値動き範囲:
$5.45
$5.8394
1週間の範囲:
$5.0539
$5.85
52週間の値動き範囲:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
MNMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
5.77 | 418.29M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Evercore ISI | Outperform |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-07-24 | 開始されました | ROTH MKM | Buy |
| 2024-05-29 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-15 | 開始されました | Leerink Partners | Outperform |
| 2023-12-05 | 開始されました | Canaccord Genuity | Buy |
| 2022-12-09 | 再開されました | ROTH Capital | Buy |
| 2022-11-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-26 | 開始されました | Oppenheimer | Outperform |
| 2022-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 開始されました | ROTH Capital | Buy |
| 2021-06-28 | 開始されました | Maxim Group | Buy |
すべてを表示
Mind Medicine Inc (MNMD) 最新ニュース
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
Breakthrough: First-Ever Phase 3 LSD Depression Trial Begins at MindMed - Stock Titan
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa
MNMD Stock Forecast From 2025 To 2040 - Exla Resources
Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com Canada
MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks
Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com India
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa
MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow
MindMed appoints new Chief Commercial Officer - Investing.com
MindMed Taps Former Jazz Pharma Executive to Lead MM120 Anxiety Drug Launch - Stock Titan
MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com
MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India
What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World
Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World
Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World
Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider
Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India
Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
MindMed Advances Clinical Trials and Strengthens Financial Position - TipRanks
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months - MSN
MindMed posts strong cash position, progress on LSD treatment - Green Market Report
Earnings call transcript: MindMed misses Q4 2024 EPS forecast, stock slides - Investing.com
Mind Medicine (MindMed) Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mind Medicine (MindMed) Inc. SEC 10-K Report - TradingView
Mind Medicine reports Q4 EPS (41c), consensus (28c) - TipRanks
MIND MEDICINE Earnings Results: $MNMD Reports Quarterly Earnings - Nasdaq
Mind Medicine (MindMed) Inc. Loss At -$34.74 Mln In Q4 - Nasdaq
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates - Joplin Globe
MindMed to Present at Leerink’s Global Healthcare Conference 2025 - TipRanks
Can MindMed's Conference Appearance Signal New Brain Health Breakthroughs? - Stock Titan
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
Mind Medicine Inc (MNMD) 財務データ
収益
当期純利益
現金流量
EPS
Mind Medicine Inc (MNMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Karlin Daniel | Chief Medical Officer |
Mar 25 '25 |
Sale |
6.74 |
6,836 |
46,075 |
446,177 |
| Sullivan Mark | Chief Legal Officer |
Mar 25 '25 |
Sale |
6.74 |
6,576 |
44,322 |
316,621 |
| Liao Carrie | Chief Accounting Officer |
Mar 25 '25 |
Sale |
6.74 |
2,347 |
15,819 |
144,923 |
2.51%
大文字化:
|
ボリューム (24 時間):